ArriVent BioPharma (AVBP) announced the appointment of Brent Rice as chief commercial officer. Rice joins ArriVent with over 25 years of U.S. and global commercial experience in the biotechnology and pharmaceutical industry. Before joining ArriVent, Brent most recently served as the senior VP and global chief commercial officer, and managing director U.S. at Autolus Therapeutics (AUTL).
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVBP:
- 3 Best Stocks to Buy Now, 9/10/2025, According to Top Analysts
- ArriVent BioPharma Buy Rating: Strong Clinical Data and Strategic Positioning Highlight Potential
- Promising Market Position and Strong Clinical Results Lead to Buy Rating for ArriVent BioPharma, Inc.
- ArriVent BioPharma Announces Promising Phase 1b Study Results
- ArriVent Biopharma presents proof-of-concept data from Phase 1b FURTHER trial